Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
MicroRNAs01:22

MicroRNAs

21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
Types of RNA01:20

Types of RNA

5.8K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
5.8K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional CRISPR screens reveal TPL1 lncRNA as a regulator of triple-negative breast cancer hallmarks.

Journal of advanced research·2026
Same author

TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).

Clinical pharmacokinetics·2025
Same author

Undifferentiated melanoma: a molecular study of a fatal metastatic "atypical fibroxanthoma (AFX)".

Virchows Archiv : an international journal of pathology·2025
Same author

Translon: a single term for translated regions.

Nature methods·2025
Same author

A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.

Cell reports. Medicine·2025
Same author

Targeting Wnt signalling through LINC02418: insights from CRISPR screens.

Gut·2025

Related Experiment Video

Updated: Jul 1, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

305

Targeting and engineering long non-coding RNAs for cancer therapy.

Michela Coan1,2,3, Simon Haefliger4,5, Samir Ounzain6

  • 1School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.

Nature Reviews. Genetics
|February 29, 2024
PubMed
Summary

Long non-coding RNA (lncRNA) therapeutics offer promising cancer treatments by targeting RNA molecules. Advances in technology are overcoming challenges to develop effective, personalized lncRNA cancer therapies.

More Related Videos

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

8.9K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

Related Experiment Videos

Last Updated: Jul 1, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

305
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

8.9K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • RNA therapeutics (RNATx) target diseases using RNA molecules.
  • Long non-coding RNAs (lncRNAs) are key regulators of oncogenic networks.
  • lncRNAs present unique therapeutic potential and development challenges.

Purpose of the Study:

  • Review the emerging field of lncRNA therapeutics for oncology.
  • Highlight the strengths and challenges of lncRNAs in RNATx.
  • Outline steps for developing effective lncRNA cancer treatments.

Main Methods:

  • Review of current advances in genome editing, oligonucleotide chemistry, multi-omics, and RNA engineering.
  • Analysis of lncRNA properties relevant to therapeutic development.
  • Discussion of the broader RNATx framework.

Main Results:

  • lncRNAs offer distinct therapeutic advantages over protein-coding genes.
  • Technological advancements are enabling efficient lncRNA drug discovery pipelines.
  • Specific strategies are needed to overcome lncRNA development hurdles.

Conclusions:

  • lncRNA therapeutics hold significant promise for personalized cancer treatment.
  • Further development is required to ensure effective, durable, and tolerable therapies.
  • This review provides a roadmap for advancing lncRNA-based oncology treatments.